SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Comment Letter for Synergy CHC Corp. (SNYR) (CIK 0001562733) (SNYRQ) — May 21, 2026

Synergy CHC Corp. (SNYR) (CIK 0001562733)
Date: May 21, 2026 · CIK: 0001562733 · Accession: 0000000000-26-005198

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-295964

Date
May 21, 2026
Author
Jack Ross
Form
UPLOAD
Company
Synergy CHC Corp. (SNYR) (CIK 0001562733)

Letter

May 21, 2026 Jack Ross Chief Executive Officer Synergy CHC Corp. 770 Roosevelt Trail STE 8 #1016 N. Windham, Maine 04062 Re: Synergy CHC Corp. Registration Statement on Form S-1 Filed May 15, 2026 File No. 333-295964 Dear Jack Ross: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Chris Edwards at 202-551-6761 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Michael K. Bradshaw, Jr.

Show Raw Text
May 21, 2026
Jack Ross
Chief Executive Officer
Synergy CHC Corp.
770 Roosevelt Trail STE 8 #1016
N. Windham, Maine 04062
Re: Synergy CHC Corp.
Registration Statement on Form S-1
Filed May 15, 2026
File No. 333-295964
Dear Jack Ross:
 This is to advise you that we have not reviewed and will not review your registration
statement.
 Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that
the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
 Please contact Chris Edwards at 202-551-6761 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Michael K. Bradshaw, Jr.